UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | FLORIDA | 26-3667538 | | --- | --- | | (State or other jurisdiction | (I.R.S. Employer | | of incorporation or organization) | Identification No.) | | 1301 Concord Terrace, Sunrise, Florida | 33323 | (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (954) 384-0175 Securities registered pursuant to Section 12(b) of the Act: ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-12111 Mednax, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of Incorporation ...

Financial Data and Key Metrics Changes - Revenue for the quarter was $473 million, exceeding internal expectations, with adjusted EBITDA of $66 million [10][48] - Adjusted EBITDA for 2021 is now expected to be above $240 million, an increase from the previous expectation of at least $220 million [10][49] - Operating cash flow for the second quarter was strong at $70 million, with cash at the end of the quarter at $338 million, up from $270 million at the end of the first quarter [48] Business Line Data and Key Metrics Changes - Total patient volumes increased by 1.3% compared to the second quarter of 2019, with hospital-based services up by 10 basis points and office-based services up by 5.2% [9][10] - Pediatric intensive care unit volumes were up 11.5% compared to the second quarter of 2019, while pediatric surgery volumes increased by 8% and maternal fetal medicine volumes rose by 9% [29][30] Market Data and Key Metrics Changes - The payer mix remained favorable year-over-year for the second consecutive quarter, with non-government volume up about 35 basis points [9][73] - Government reimbursement as a percentage of revenue decreased to 24% in Q2 2021 from 27% in 2020, indicating a shift in payer mix [78] Company Strategy and Development Direction - The company is focusing on building momentum in its core services and enhancing patient access, which has already added approximately $2 million to the top line in Q2 [12][13] - There is a strategic emphasis on expanding into children's primary and urgent care, with plans for new clinic openings and investments in this area [18] - The company is also making significant progress in improving operational efficiency through restructuring and technology upgrades, including transitioning revenue cycle management to R1 [42][45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving adjusted EBITDA above $270 million in 2022, driven by ongoing growth initiatives and efficiency improvements [21][49] - The rise in COVID-19 cases due to the Delta variant poses risks, but management remains optimistic about the recovery and growth trajectory [11][12] Other Important Information - The company completed several acquisitions, including child neurology consultants, to enhance its specialty services [16] - A significant data center consolidation and the implementation of an Oracle ERP solution were completed, which are expected to improve operational efficiency [45] Q&A Session Summary Question: NICU days increased more than birth numbers - Management explained that the NICU admission rate had reverted to trend after being below trend in 2020, leading to the observed differential [53][54] Question: Impact of vaccine approvals for under 12 population - Management indicated that while primary care pediatricians are involved in vaccinations, the overall impact on the company may not be significant [55] Question: Acquisition strategy and expansion into other specialties - Management confirmed a broad strategy to provide women's and children's health services, including subspecialties beyond traditional areas [56][57] Question: G&A efficiency opportunities - Management highlighted ongoing efforts to improve efficiency and reduce G&A costs through focused operations and restructuring [60][62] Question: Impact of managed care changes in Texas - Management acknowledged the challenges but expressed optimism about returning to network status with payers [68][69] Question: Sustainability of payer mix changes - Management noted that the current payer mix reflects a return to historical trends, but it is uncertain if this will stabilize at the new levels [78][79] Question: EBITDA margin expansion expectations - Management explained that recent investments in technology and infrastructure have impacted margins, but they expect improvements as these initiatives take effect [81][84] Question: Long-term EBITDA growth outlook - Management expressed optimism about future growth, indicating that they expect to exceed $270 million in adjusted EBITDA and continue to grow beyond that [99][100]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-12111 Mednax, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of Incorporation or or ...

Financial Data and Key Metrics Changes - The company's net revenue grew by $5.5 million or just over 1% year-over-year, with same unit revenue increasing by 2.5% year-over-year [37] - Adjusted EBITDA for Q1 2021 was $45 million, which is still below the first quarter of 2019, reflecting an 18% decline compared to Q1 2019 [16][17] - The company expects 2021 adjusted EBITDA to be at or above $220 million, with a focus on recovering to pre-pandemic levels [15][70] Business Line Data and Key Metrics Changes - Patient volumes improved throughout Q1, with same unit growth in March across all service lines except for PeekYou and pediatric hospitalist services [39] - NICU days for the quarter were down slightly more than total births at hospitals where NICU coverage is provided, indicating a modest year-over-year decline in average length of stay [40] - Same unit volumes declined approximately 3% compared to the same period in 2019, with hospital-based volume down more than office-based volume [41] Market Data and Key Metrics Changes - The payor mix improved by 110 basis points compared to 2020, contributing roughly $5 million in revenue or over 1% to pricing growth for the quarter [42] - The company recorded about $8 million in revenue from the Provider Relief Fund during the quarter, which positively impacted overall revenue [37] Company Strategy and Development Direction - The company aims to reinforce its position as a leading provider of women's and children's healthcare, focusing on patient care and operational efficiency [20] - Plans include expanding pediatric primary and urgent care services to enhance patient access and strengthen community relationships [30][31] - A marketing campaign has been launched to increase brand awareness and trust in the company's services [33] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the ongoing volatility in operating results and the uncertain nature of recovery from COVID-19 impacts [18][19] - The company is optimistic about achieving a run rate of $270 million in adjusted EBITDA post-COVID, driven by operational improvements and strategic initiatives [19] - Management emphasized the importance of taking great care of patients as a core principle guiding the company's operations [21] Other Important Information - The company ended the quarter with $270 million in cash and net debt of $730 million, indicating a leverage ratio just over 3x [47] - G&A expenses were down nearly $1 million year-over-year, despite incurring costs related to transitional services provided to buyers of anesthesia and radiology medical groups [44] Q&A Session Summary Question: Understanding volume recovery for the rest of the year - Management noted that while there has been upward volatility in volumes, it is too early to make bullish predictions about recovery trends [52][54] Question: Impact of TSA on guidance - Management indicated that there will be residual costs from winding down TSA services, which may not be one-for-one with revenue collection [58] Question: Commercial mix improvement - Management stated that the payor mix is returning to expected levels after an anomaly in the fourth quarter [64] Question: Update on deal pipeline and acquisitions - Management confirmed a strong pipeline for both organic growth and acquisitions, particularly in pediatrics and obstetrics [67] Question: Guidance for Q2 EBITDA - Management provided a consensus estimate for Q2 EBITDA around $50 million to $55 million, emphasizing caution due to ongoing volatility [70][100]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 Mednax, Inc. (Exact name of registrant as specified in its charter) Florida 26-3667538 (State or other jurisdictio ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-12111 MEDNAX, INC. (Exact name of registrant as specified in its charter) FLORIDA 26-3667538 (State or other jurisdiction of inco ...

MEDNAX, Inc. (NYSE:MD) Q3 2020 Earnings Conference Call November 6, 2020 9:00 AM ET Company Participants Charles Lynch - VP of Strategy and IR Mark Ordan - CEO Marc Richards - EVP & CFO Roger Hinson - President, Pediatrix and Obstetrix Medical Groups Conference Call Participants A.J. Rice - Credit Suisse Brian Tanquilut - Jefferies Gary Taylor - JP Morgan Whit Mayo - UBS Kevin Fischbeck - Bank of America Nick Spiekhout - William Blair Pito Chickering - Deutsche Bank Ralph Giacobbe - Citi Operator Ladies a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-12111 MEDNAX, INC. (Exact name of registrant as specified in its charter) Florida 26-3667538 (State or other jurisdi ...

MEDNAX, Inc. (NYSE:MD) Q2 2020 Earnings Conference Call July 30, 2020 10:00 AM ET Company Participants Charles Lynch - Investor Relations Mark Ordan - Chief Executive Officer Stephen Farber - Chief Financial Officer Conference Call Participants A.J. Rice - Cr??dit Suisse Ralph Giacobbe - Citi Kevin Fischbeck - Bank of America Nick Spiekhout - William Blair Pito Chickering - Deutsche Bank Brian Tanquilut ??? Jefferies Rishi Parekh - Barclays Whit Mayo - UBS Operator Ladies and gentlemen, thank you for standi ...